Establishing a complementary diagnostic for anti-PD-1 immune checkpoint inhibitor therapy

The role of tumor PD-L1 expression was investigated across the nivolumab clinical development program. Phase III nivolumab trials have shown that patients with tumors not expressing PD-L1 may benefit; therefore, testing is not required to select patients for therapy. The Dako PD-L1 IHC 28-8 pharmDx...

Descripción completa

Detalles Bibliográficos
Autores principales: Novotny, J. F., Cogswell, J., Inzunza, H., Harbison, C., Horak, C., Averbuch, S.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2016
Materias:
Industry Corner: Perspectives and Controversies
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5035792/
https://www.ncbi.nlm.nih.gov/pubmed/27502705
http://dx.doi.org/10.1093/annonc/mdw288
_version_ 1782455451953135616
author Novotny, J. F.
Cogswell, J.
Inzunza, H.
Harbison, C.
Horak, C.
Averbuch, S.
author_facet Novotny, J. F.
Cogswell, J.
Inzunza, H.
Harbison, C.
Horak, C.
Averbuch, S.
author_sort Novotny, J. F.
collection PubMed
description The role of tumor PD-L1 expression was investigated across the nivolumab clinical development program. Phase III nivolumab trials have shown that patients with tumors not expressing PD-L1 may benefit; therefore, testing is not required to select patients for therapy. The Dako PD-L1 IHC 28-8 pharmDx assay may be used to determine tumor PD-L1 expression as a complementary and informative test.
format Online
Article
Text
id pubmed-5035792
institution National Center for Biotechnology Information
language English
publishDate 2016
publisher Oxford University Press
record_format MEDLINE/PubMed
spelling pubmed-50357922016-09-27 Establishing a complementary diagnostic for anti-PD-1 immune checkpoint inhibitor therapy Novotny, J. F. Cogswell, J. Inzunza, H. Harbison, C. Horak, C. Averbuch, S. Ann Oncol Industry Corner: Perspectives and Controversies The role of tumor PD-L1 expression was investigated across the nivolumab clinical development program. Phase III nivolumab trials have shown that patients with tumors not expressing PD-L1 may benefit; therefore, testing is not required to select patients for therapy. The Dako PD-L1 IHC 28-8 pharmDx assay may be used to determine tumor PD-L1 expression as a complementary and informative test. Oxford University Press 2016-10 2016-08-08 /pmc/articles/PMC5035792/ /pubmed/27502705 http://dx.doi.org/10.1093/annonc/mdw288 Text en © The Author 2016. Published by Oxford University Press on behalf of the European Society for Medical Oncology. http://creativecommons.org/licenses/by-nc/4.0/ This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/4.0/), which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited. For commercial re-use, please contact journals.permissions@oup.com
spellingShingle Industry Corner: Perspectives and Controversies
Novotny, J. F.
Cogswell, J.
Inzunza, H.
Harbison, C.
Horak, C.
Averbuch, S.
Establishing a complementary diagnostic for anti-PD-1 immune checkpoint inhibitor therapy
title Establishing a complementary diagnostic for anti-PD-1 immune checkpoint inhibitor therapy
title_full Establishing a complementary diagnostic for anti-PD-1 immune checkpoint inhibitor therapy
title_fullStr Establishing a complementary diagnostic for anti-PD-1 immune checkpoint inhibitor therapy
title_full_unstemmed Establishing a complementary diagnostic for anti-PD-1 immune checkpoint inhibitor therapy
title_short Establishing a complementary diagnostic for anti-PD-1 immune checkpoint inhibitor therapy
title_sort establishing a complementary diagnostic for anti-pd-1 immune checkpoint inhibitor therapy
topic Industry Corner: Perspectives and Controversies
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5035792/
https://www.ncbi.nlm.nih.gov/pubmed/27502705
http://dx.doi.org/10.1093/annonc/mdw288
work_keys_str_mv AT novotnyjf establishingacomplementarydiagnosticforantipd1immunecheckpointinhibitortherapy
AT cogswellj establishingacomplementarydiagnosticforantipd1immunecheckpointinhibitortherapy
AT inzunzah establishingacomplementarydiagnosticforantipd1immunecheckpointinhibitortherapy
AT harbisonc establishingacomplementarydiagnosticforantipd1immunecheckpointinhibitortherapy
AT horakc establishingacomplementarydiagnosticforantipd1immunecheckpointinhibitortherapy
AT averbuchs establishingacomplementarydiagnosticforantipd1immunecheckpointinhibitortherapy

Ejemplares similares